A Phase II Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-grade B-cell Lymphoma With Rearrangements of MYC and BCL2 and/or BCL6
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2019
Price : $35 *
At a glance
- Drugs CPI 613 (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma
- Focus Therapeutic Use
- 02 Dec 2019 According to a Rafael Pharmaceuticals media release, announced the expansion of its Phase 2 clinical trial of CPI-613 (devimistat) for patients with relapsed or refractory Burkitts lymphoma/leukemia.
- 06 Nov 2019 According to the Trial design released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019), an interim analysis for toxicity will be conducted after the first 10 study participants have completed two complete cycles or have come off study.
- 06 Nov 2019 Trial design released at the 61st Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem 2019).